Description:

NCIC MA.32 Telephone Follow-Up Report A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=81DC7457-3943-EA84-E040-BB89AD43055B

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=81DC7457-3943-EA84-E040-BB89AD43055B

Keywords:
Versions (3) ▾
  1. 8/27/12
  2. 1/9/15
  3. 9/27/21
Uploaded on:

September 27, 2021

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT01101438 Follow-Up - NCIC MA.32 Telephone Follow-Up Report - 3025096v1.0

No Instruction available.

  1. StudyEvent: NCIC MA.32 Telephone Follow-Up Report
    1. No Instruction available.
Timing Of Report - Telephone Follow-up
Metformin/placebo Administration
Has subject taken protocol medication every day
Dose Modification Reason (If no, please enter the reasons for dose modifications in the table below:)
Was this dose modification or addition/omission as per protocol guidelines
Serious Adverse Event - Question
Did the patient experience a Serious Adverse Event, as defined in protocol section 11, during this reporting period
Adverse Events On Treatment - Question
Were any additional adverse events experienced by the patient
Adverse Events
Would you like to carry forward the adverse events (indicated as continuing) from the previous reporting period
CTCAE Term
AE Ongoing
Seriousness Attributed to Adverse Event
Attribution

Similar models